NewCo News: CureFAKtor Tackles Pancreatic Cancer Via FAK/Chemo Combo
By Jennifer Boggs
Wednesday, February 9, 2011
Since it was founded in 2008, CureFAKtor Pharmaceuticals LLC remained under the radar until recent orphan designation for lead product CFAK-C4 in pancreatic cancer not to mention some impressive preclinical data at the ASCO Gastrointestinal Cancers Symposium last month put the firm on the map.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.